Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Patients with myeloma that has either not responded to previous treatment or has returned
after previous treatment will be given a combination of the drugs bendamustine and
bortezomib.
The bortezomib and bendamustine will be given using an intravenous line (IV) on days 1 and 4
of each cycle, with bortezomib being given first, before each dose of bendamustine. Each
cycle will be 28 days long, so patients will be treated the first week of each cycle and then
have 3 weeks 'off' (without any treatment). Disease assessments will be performed on day 22
of each cycle. Patients will receive the study drugs until their disease progresses or they
are withdrawn from the study.
In other studies, bendamustine seems to work well with other drugs. Thus, this study hopes to
show that the combination of bortezomib and bendamustine will have activity in
relapsed/refractory myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health